Deuterated psilocin added to antidepressants: Helus reports the main APPROACH trial result

Related Articles

Psiconáutica Editorial Team · November 17, 2026

Read more  MDMA-assisted therapy and PTSD: a low-certainty living review

At a glance

  • Reported result: in the phase 3 APPROACH trial, two doses of HLP003 added to an antidepressant reduced MADRS scores 7.6 points more than placebo at week 6, according to Helus Pharma.
  • What was compared: the 222 adults analyzed stayed on their antidepressant and received psychological support. The figure estimates what HLP003 adds, not how it performs against another treatment.
  • What is missing: there is no peer-reviewed paper, safety is summarized in a few lines and the drug is not approved.

Helus Pharma, the company whose legal name was Cybin until October 1, 2026, announced on November 16 the main results of APPROACH, a phase 3 trial of HLP003. It is a deuterated psilocin. Psilocin is the molecule the body converts the psilocybin in mushrooms into; in this variant, some hydrogen atoms have been replaced by deuterium, a heavier isotope. The company says the study met its primary endpoint. The figures in this article come from that press release and the trial registry. There is not yet a scientific publication that would allow the methods and full data to be reviewed.

What was measured

The official registry entry, NCT06564818, keeps the APPROACH acronym, the sponsor Cybin IRL and the drug’s earlier code, CYB003. It describes a randomized, double-blind, placebo-controlled trial at 45 sites in the United States. Eligible participants were adults aged 18 to 85 with moderate to severe major depression who had improved by less than 50% on a single antidepressant. Each person received two sessions, about three weeks apart, with 16 mg of HLP003 or placebo, always with structured psychological support. The registry lists 223 people enrolled; the press release analyzes 222 (112 on HLP003 and 110 on placebo).

The primary measure was the MADRS, a ten-item clinical interview in which a higher score indicates more severe depression. A score of at least 24 was required to enter. Baseline means were 32.7 and 33.8 points. At week 6, the company reports a drop of 19.5 points with HLP003 and 11.9 with placebo, an adjusted mean difference of 7.6 points (p < 0.0001; effect size 0.653). On day 2 the difference was 5.0 points, and at week 12, the key secondary endpoint, 7.0. Remission, defined as a MADRS score of 10 or less, reached 50.9% with HLP003 and 18.2% with placebo at week 6. The public registry only lists MADRS measurements up to day 42; the week-12 figure comes from the press release.

Read more  Medical cannabis and Schedule III: a September US stay order

What the trial actually compares

Both groups kept their antidepressant and support. The difference therefore estimates what HLP003 adds to a treatment that was not fully working. It does not show how it compares with another drug or what effect it has without an antidepressant. Nor can it be extended to treatment-resistant depression, which the registry excluded, or to people with bipolar disorder, psychosis, significant suicide risk, more than ten previous psychedelic experiences or any in the past year.

The placebo group improved by 11.9 points, a reminder of how much expectation, support and natural course matter. In addition, with a substance whose effects are noticeable, many participants may guess what they received. The press release does not say whether blinding was assessed.

Safety, in a few lines

Helus describes HLP003 as “generally well tolerated,” with adverse events mostly mild or moderate, transient and primarily limited to the dosing day. The release lists three serious adverse events that Helus classified as related to HLP003. The sponsor’s presentation identifies them as two reports of depression and one suicide attempt. On the results call, the chief medical officer said the attempt occurred 55 days after the second dose in a participant who had not responded to treatment. Helus says its assessment found no suicidality signal. The cause of the event remains uncertain, and the public information is still too limited to weigh benefits and risks fully.

Read more  Plant tryptamines: a synthetic-biology proof of concept

What it means

APPROACH is the first of two pivotal trials. The company expects results from the second, EMBRACE, in the fourth quarter of 2027. HLP003 holds FDA Breakthrough Therapy designation, which speeds up dialogue with the regulator but is not an approval. It is a relevant but provisional signal, in a year when other companies, such as Compass, have already reached the stage of an FDA application. HLP003 is only available in trials, and its result does not carry over to mushroom use: dose, purity, participant selection and supervision are different. On psilocin itself, see a trial that compared it with psilocybin and our guide to psychedelic science and therapy.

Story spotted through coverage by Cannabis Magazine (in Spanish). The data were checked against the registry and the sponsor’s materials.

Sources

Image: illustrative image of medicine capsules. It does not show HLP003 and is not from the trial. Photo: Aney, Wikimedia Commons, licensed under CC BY-SA 3.0.

Educational content produced from a harm-reduction perspective and with respect for individual freedom. It does not replace information from a healthcare professional and does not aim to encourage or condemn any use.

More on this topic

Comments

Advertisementspot_img

Popular stories